Progress of immunotherapy for acute leukemia
10.3760/cma.j.issn.1009-9921.2019.08.011
- VernacularTitle:急性白血病免疫治疗研究进展
- Author:
Weiwei HU
1
;
Siguo HAO
Author Information
1. 上海交通大学医学院附属新华医院血液科 200092
- Keywords:
Acute leukemia;
Immunotherapy;
Bispecific T-cell engagers;
Chimeric antigen receptor T-cell therapy;
Immune checkpoint inhibitor
- From:
Journal of Leukemia & Lymphoma
2019;28(8):498-501
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the immunotherapy for hematological malignancies, especially acute leukemia (AL), has made great progress from bench to bedside and developed rapidly. For a long time, the immunotherapy targeted to AL mainly faces some problems, such as the identification and selection of specific antigens of leukemia cells, the enhancement of immunogenicity of leukemia-associated antigens, the promotion of endogenous immune response, and overcome the immunosuppression in tumor microenvironment. Therefore, the AL immunotherapy strategies in recent years are mainly aimed at these problems and achieved rapid development, including monoclonal antibodies against leukemia cells surface antigens and monoclonal antibodies conjugated cytotoxic drugs, bispecific antibodies, especially bispecific T cell engager monoclonal antibodies, chimeric antigen receptor T-cells, immune checkpoint inhibitors, dendritic cells and exosomes-based vaccines. This review will briefly introduce the research progress of the basic and clinical application of AL immunotherapy.
